Clinical trials: why multi-arms are better than two
by Guest Author on 25 Jul 2014
In their quest to speed up the discovery of new treatments for patient benefit, MRC researchers at the MRC Clinical Trials Unit propose an efficient solution: the multi-arm clinical trial. But how do these trials work and why should the traditional two-arm clinical trial be the exception and not the rule? We asked Annabelle South, Policy, Communications & Research Impact Coordinator at the MRC Clinical Trials Unit, to explain this change in approach, as published in The Lancet.
Randomised controlled trials are the best way of finding out if new treatments are better than the current standard treatment. But trials take a long time to set up and run, and can be expensive.
Here at the MRC Clinical Trials Unit at UCL we are keen to find faster and more efficient ways of working out which treatments work best, so patients can benefit sooner. That’s why we are urging researchers and drugs companies to move away from the traditional ‘two-arm’ approach to trials, and adopt more innovative, efficient approaches like the multi-arm trial.
The usual design for a randomised controlled trial is to randomly allocate volunteer patients to receive either the new treatment or the current standard one. The trial doctors and nurses closely monitor both groups (or arms). At the end of the trial, we analyse all the data to see if the new treatment works better than the old one.
This design does work – it tells us whether the new treatment is effective and safe. But about half of trials find the new treatment is no better than the existing one, leaving us back at the drawing board.
We believe that multi-arm trials can offer advantages over two-arm trials, and here’s how:
- Increase your chance of finding an effective treatment
If you increase the number of new treatments you are testing in a trial, you increase the chances that one of them will be better. This means that at the end of all your efforts you are much more likely to have discovered something that can improve the lives of people with the disease.
- Test more treatments at once
Multi-arm trials allow you to test many more treatments than would ever be done in two-arm trials – you don’t have to guess in advance which new drug is most likely to work, you can test several good candidates at once.
- Halve your costs
It’s much cheaper to assess several new treatments simultaneously in one multi-arm trial, rather than run several separate trials – we estimate that costs are halved.
- Speed up recruitment of participants
Patients and doctors support it. Some people have been concerned that multi-arm trials may be too complex for doctors and patients to understand. Our experience shows this is not the case – in fact, patients and doctors are very supportive of multi-arm trials, asking “why don’t you do all your trials this way?” Our multi-arm trials recruit participants faster than comparable two-arm trials.
Going one step further
Multi-arm, multi-stage (MAMS) trials take this one step further. They not only test several treatments at once, but can also stop recruiting patients to a particular arm part way through, if a treatment is not looking promising enough. They even allow us to add new treatments to the trial when they are ready for testing. This approach is even more efficient, meaning you don’t have to have gaps between stopping a trial and starting a new one, and may not need to set up a separate new trial to test a new treatment. This saves many years.
One example of this is the STAMPEDE trial, looking at how to treat prostate cancer. It has stopped and added arms as it’s gone along. It now has more than 5,500 participants, making it the largest prostate cancer treatment trial ever. It will assess eight new treatments in 15 years – something that would have taken at least 40 years in separate sequential trials.
The advantages of multi-arm trials over two-arm trials are such that two-arm trials should be the exception, not the rule. We urge doctors and patient groups to push for more multi-arm trials, and fewer two-arm trials, so we can identify effective new treatments faster and more efficiently.